These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2247261)

  • 41. [The treatment of peptic ulcer].
    Zeligman VS; Shmakov VN; Radugina GS; Chernykh SN; Zazimko AS
    Vrach Delo; 1989 Apr; (4):7-10. PubMed ID: 2756693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds.
    Scarpignato C; Pelosini I
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antisecretory and mucosa-protecting drugs in the acute care of peptic ulcer. Review of action principles, healing rates and side effects of approved ulcer drugs and drugs under clinical trial].
    Simon B; Müller P; Dammann HG
    Fortschr Med; 1984 Jul; 102(25-26):683-7. PubMed ID: 6147304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Controversy and trends in ulcer therapy. 1: Treatment of ulcer manifestation].
    Berndt H
    Z Arztl Fortbild (Jena); 1993 Aug; 87(8):635-42. PubMed ID: 8379202
    [No Abstract]   [Full Text] [Related]  

  • 45. [Calcium containing antacids and acid rebound. Testing with intragastric titration and extragastric measurement of pH].
    Weingart J; Ottenjann R
    Fortschr Med; 1977 Aug; 95(32):1987-9. PubMed ID: 21129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Synthetic analog of prostaglandin E2 (enprostil) in the treatment of peptic ulcer].
    Grigor'ev PIa; Isakov VA
    Sov Med; 1991; (3):39-43. PubMed ID: 1909055
    [No Abstract]   [Full Text] [Related]  

  • 47. [Diagnostic value of cholinolytics in the surgical treatment of peptic ulcer].
    Zaĭtsev VT; Buianov VM; Boĭko VV; Lagoda AE
    Khirurgiia (Mosk); 1991 Mar; (3):36-9. PubMed ID: 1861383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic and cost effectiveness of proton pump inhibitor regimens for idiopathic or drug-induced peptic ulcer complication.
    Nam DH; Park SY; Park JM; Kim SC
    Arch Pharm Res; 2011 Mar; 34(3):443-9. PubMed ID: 21547676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease.
    May B
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():113-6. PubMed ID: 2657280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The modern treatment of peptic ulcer disease].
    Soffer E; Bar-Meir S
    Harefuah; 1986 Feb; 110(4):185-7. PubMed ID: 3522377
    [No Abstract]   [Full Text] [Related]  

  • 51. The use of antacids in the treatment of peptic ulcer.
    Grossman MI
    Scand J Gastroenterol Suppl; 1980; 58():37-40. PubMed ID: 6988940
    [No Abstract]   [Full Text] [Related]  

  • 52. [Guidelines for good practice: anti-ulcer agents, indications in the adult. French Agency for Health Safety of Health Products].
    Therapie; 1999; 54(5):509-17. PubMed ID: 10667082
    [No Abstract]   [Full Text] [Related]  

  • 53. [Role of prostanoids in the pathogenesis and therapy of peptic ulcer].
    Fich A; Stalnikowicz R; Goldin E; Eliakim R; Wengrower D; Ligumsky M; Karmeli F; Rachmilewitz D
    Harefuah; 1986 Nov; 111(10):292-5. PubMed ID: 3817615
    [No Abstract]   [Full Text] [Related]  

  • 54. Present and future treatment of peptic ulcer and potential role of DE-NOL.
    Scand J Gastroenterol Suppl; 1982; 80():49-57. PubMed ID: 6761852
    [No Abstract]   [Full Text] [Related]  

  • 55. [Antacids: what role in the treatment of ulcer disease?].
    Galmiche JP; Bruley des Varannes S; Ducrot F
    Gastroenterol Clin Biol; 1986; 10(6-7):481-5. PubMed ID: 2875914
    [No Abstract]   [Full Text] [Related]  

  • 56. Update in treatment of peptic ulcer disease.
    Schubert TT
    Mo Med; 1984 Nov; 81(11):723-7. PubMed ID: 6095013
    [No Abstract]   [Full Text] [Related]  

  • 57. [New therapeutic approaches to peptic ulcer using mucosal protective agents].
    Jin M; Otaka M; Watanabe S
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():377-81. PubMed ID: 11979810
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of antiulcer potential of Mimusops hexandra in experimental gastro duodenal ulcers.
    Modi KP; Lahiri SK; Goswami SS; Santani DD; Shah MB
    J Complement Integr Med; 2012 Aug; 9():Article 18. PubMed ID: 22944719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current problems in the treatment of gastroduodenal ulcer].
    Dumitraşcu D
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1986; 38(5):401-11. PubMed ID: 2881332
    [No Abstract]   [Full Text] [Related]  

  • 60. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.